AstraZeneca(US:AZN) Zhong Guo Xin Wen Wang·2026-01-30 12:57Group 1 - The core viewpoint is that AstraZeneca's CEO emphasizes China's indispensable role in the global pharmaceutical innovation ecosystem [1][2] - AstraZeneca plans to invest over 100 billion RMB in China by 2030, driven by the significant demand for drugs from Chinese patients and the country's strong innovation environment [1] - The company currently operates two global strategic R&D centers in Beijing and Shanghai, with multiple production bases in China supplying innovative medicines to over 70 markets worldwide [1] Group 2 - Future plans include establishing two new production bases in China focused on cell therapy and radiolabeled drugs, alongside increasing R&D investment and expanding the production network [1] - The CEO believes that UK-China collaboration in life sciences can benefit both nations and global patients through joint innovation, with significant potential in areas like green transformation and artificial intelligence [1][2]